EndlessMedical Devices
New paradigm in Mechanical Ventilation
Actively Hiring
Overview
Employees
Locations
Chesapeake Beach
Chesapeake Beach
We are developing Mechanical Ventilation 2.0 (MV 2.0) with improvements (MV 2.5).
In 2022, our innovative approach was recognized with a USPTO patent, marking the birth of our startup. MV 2.0-2.5 is designed to address acute respiratory distress syndrome (ARDS) and provide superior solution to contemporary ventilators.
Hypothetically, it improves:
Clinical Outcomes:
Improved patient survival and decreased mortality.
Prevention of ventilator-associated pneumonia.
No need for permissive hypercapnia in ARDS.
Ability to independently set target pO2 and pCO2 levels.
Effective regardless of the type of pathogen, whether new viral strains or toxic warfare agents, eliminating the need for specific studies for each strain, unlike vaccines.
Downstream benefits include reduced antibiotic usage and fewer Clostridium difficile infections.
Financial Outcomes:
Shorter time on the ventilator.
Reduced ICU and hospital stay durations.
Faster patient recovery and quicker return to work.
Reduced utilization of healthcare resources.
Potential for higher reimbursement in institutions with better clinical outcomes (e.g., fewer Clostridium difficile infections).
Staff Safety:
Separation of inspiratory and expiratory lumens prevents the release of pathogens into the patient room or hallway.
The COVID-19 pandemic has tragically highlighted the limitations of current ventilators. As a healthcare professional, it was heart-wrenching to see patients succumb to these limitations, knowing there could be a better solution. If, like me, you believe technology should save lives and not limit them, I invite you to join our mission.
About Our Startup:
We are committed to improve ICU survival rates. While COVID-19 has subsided, the threat persists, and other respiratory crises, such as influenza (including avian), aspiration pneumonia, and neonatal respiratory distress syndrome (NRDS), continue to endanger lives every day.
In 2022, our innovative approach was recognized with a USPTO patent, marking the birth of our startup. MV 2.0-2.5 is designed to address acute respiratory distress syndrome (ARDS) and provide superior solution to contemporary ventilators.
Hypothetically, it improves:
Clinical Outcomes:
Improved patient survival and decreased mortality.
Prevention of ventilator-associated pneumonia.
No need for permissive hypercapnia in ARDS.
Ability to independently set target pO2 and pCO2 levels.
Effective regardless of the type of pathogen, whether new viral strains or toxic warfare agents, eliminating the need for specific studies for each strain, unlike vaccines.
Downstream benefits include reduced antibiotic usage and fewer Clostridium difficile infections.
Financial Outcomes:
Shorter time on the ventilator.
Reduced ICU and hospital stay durations.
Faster patient recovery and quicker return to work.
Reduced utilization of healthcare resources.
Potential for higher reimbursement in institutions with better clinical outcomes (e.g., fewer Clostridium difficile infections).
Staff Safety:
Separation of inspiratory and expiratory lumens prevents the release of pathogens into the patient room or hallway.
The COVID-19 pandemic has tragically highlighted the limitations of current ventilators. As a healthcare professional, it was heart-wrenching to see patients succumb to these limitations, knowing there could be a better solution. If, like me, you believe technology should save lives and not limit them, I invite you to join our mission.
About Our Startup:
We are committed to improve ICU survival rates. While COVID-19 has subsided, the threat persists, and other respiratory crises, such as influenza (including avian), aspiration pneumonia, and neonatal respiratory distress syndrome (NRDS), continue to endanger lives every day.
Industries
Healthcare
Medical Devices
